64Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression

被引：5
|
作者：
Lee, Inki [1 ]
Lim, Ilhan [1 ,2 ,3 ,6 ]
Lee, Kyo Chul [2 ]
Kang, Hye Jin [4 ,5 ]
Lim, Sang Moo [1 ]
机构：
[1] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Nucl Med, Seoul, South Korea
[2] Korea Inst Radiol & Med Sci, Res Inst Radiol & Med Sci, Div Appl RI, Seoul, South Korea
[3] Univ Sci & Technol, Dept Radiol & Med Oncol Sci, Seoul, South Korea
[4] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea
[5] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Internal Med, Div Hematol Oncol, 75,Nowon Ro, Seoul, South Korea
[6] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Nucl Med, 75,Nowon Ro, Seoul, South Korea
来源：
CLINICAL NUCLEAR MEDICINE | 2023年 / 48卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
Cu-64-DOTA-rituximab; B-cell lymphoma; CD20; antigen; positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET;
D O I：
10.1097/RLU.0000000000004378
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Cu-64-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with F-18-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no discernible Cu-64-DOTA-rituximab uptake in the tumor other than lymphoma. Cu-64-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma because of imaging the CD20 expression.
引用
收藏
页码：E82 / E83
页数：2
相关论文
共 50 条
  • [31] Positron Emission Tomography of 64Cu-DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHL
    Arutselvan Natarajan
    Gayatri Gowrishankar
    Carsten H. Nielsen
    Sen Wang
    Andrei Iagaru
    Michael L. Goris
    Sanjiv Sam Gambhir
    Molecular Imaging and Biology, 2012, 14 : 608 - 616
  • [32] Positron Emission Tomography of 64Cu-DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHL
    Natarajan, Arutselvan
    Gowrishankar, Gayatri
    Nielsen, Carsten H.
    Wang, Sen
    Iagaru, Andrei
    Goris, Michael L.
    Gambhir, Sanjiv Sam
    MOLECULAR IMAGING AND BIOLOGY, 2012, 14 (05) : 608 - 616
  • [33] Expression and Function of Tigit in B-Cell Non-Hodgkin Lymphoma
    Yang, Zhi-Zhang
    BLOOD, 2016, 128 (22)
  • [34] Rituximab in the management of non-Hodgkin lymphoma. expressing CD20 (Egyptian single institution experience)
    Azim, HA
    Azim, HA
    Moneim, DA
    Kamal, NS
    ANNALS OF ONCOLOGY, 2005, 16 : 303 - 303
  • [35] Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma
    Blasco, Helene
    Chatelut, Etienne
    de Bretagne, Isabelle Benz
    Congy-Jolivet, Nicolas
    Le Guellec, Chantal
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 (05) : 601 - 608
  • [36] Beyond Rituximab: The Future of Monoclonal Antibodies in B-Cell Non-Hodgkin Lymphoma
    Sikder, Manzurul A.
    Friedberg, Jonathan W.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (05) : 420 - 426
  • [37] Rituximab in B-cell disorders other than non-Hodgkin's lymphoma
    Bosly, A
    Keating, MJ
    Stasi, R
    Bradstock, K
    ANTI-CANCER DRUGS, 2002, 13 : S25 - S33
  • [38] RITUXIMAB CLEARANCE IN PEDIATRIC PATIENTS WITH MAATURE B-CELL NON-HODGKIN LYMPHOMA
    Toelle, I.
    Lanvers-Kaminsky, C.
    Bethke, M.
    Randau, G.
    Rolfing, M.
    Tann, A.
    te Vrugt, M.
    Mellgren, K.
    Mueller, S.
    Burkhardt, B.
    LEUKEMIA RESEARCH, 2022, 121 : S23 - S24
  • [39] Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
    Manzurul A. Sikder
    Jonathan W. Friedberg
    Current Oncology Reports, 2008, 10
  • [40] Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
    Sikder M.A.
    Friedberg J.W.
    Current Hematologic Malignancy Reports, 2008, 3 (4) : 187 - 193
12345